SCHEMBL1420185

SCHEMBL1420185

O=C(Nc1cccc(Cl)c1)c1cccc(N2CCC(N3CCCC3)CC2)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.60
RAB9A P51151 3/20 0.60
L3MBTL1 Q9Y468 2/20 0.60
L3MBTL3 Q96JM7 1/20 0.60
KMT2A Q03164 4/20 0.56
TDP1 Q9NUW8 3/20 0.56
POLB P06746 2/20 0.56
MEN1 O00255 2/20 0.56
KDM4E B2RXH2 1/20 0.56
HTT P42858 1/20 0.56
CASP6 P55212 1/20 0.56
HDAC4 P56524 1/20 0.50
KCNQ2 O43526 1/20 0.50
MAPT P10636 2/20 0.49
LMNA P02545 1/20 0.49
ALPL P05186 1/20 0.49
ALPI P09923 1/20 0.49
ALPG P10696 1/20 0.49
KCNK3 O14649 1/20 0.49
KCNK9 Q9NPC2 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1420605 0.85 NPY2R (0.51) NPC1RAB9AL3MBTL1L3MBTL3KMT2A
SCHEMBL1420411 0.84 NPY2R (0.52) NPC1RAB9AL3MBTL1L3MBTL3TDP1
SCHEMBL1420138 0.84 MAPT (0.58) L3MBTL1L3MBTL3KMT2ATDP1MEN1
SCHEMBL1420220 0.83 NPC1 (0.58) NPC1RAB9AL3MBTL1L3MBTL3KMT2A
SCHEMBL1420046 0.83 SMN1; SMN2 (0.50) NPC1RAB9AKMT2ATDP1MEN1
SCHEMBL14529001 0.82 L3MBTL3 (0.65) L3MBTL1L3MBTL3POLBHTTHDAC4
SCHEMBL14528638 0.78 L3MBTL3 (0.59) L3MBTL1L3MBTL3POLBHTTHDAC4
SCHEMBL1420053 0.78 L3MBTL3 (0.72) L3MBTL1L3MBTL3KMT2ATDP1MEN1
SCHEMBL12552632 0.77 L3MBTL3 (0.76) L3MBTL1L3MBTL3KMT2ATDP1POLB
SCHEMBL18502051 0.77 NR1H4 (0.53) NPC1RAB9AL3MBTL1L3MBTL3KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2011524365-A 2011-09-01 JP claimed
US-20110144107-A1 COMPOUNDS AND COMPOSITIONS USEFUL FOR THE TREATMENT OF MALARIA IRM LLC (BM) 2011-06-16 US claimed
EP-2297097-A2 COMPOUNDS AND COMPOSITIONS USEFUL FOR THE TREATMENT OF MALARIA IRM LLC (BM) 2011-03-23 EP claimed
WO-2009152356-A2 COMPOUNDS AND COMPOSITIONS USEFUL FOR THE TREATMENT OF MALARIA IRM LLC (BM) 2009-12-17 WO claimed
US-20110144107-A1 COMPOUNDS AND COMPOSITIONS USEFUL FOR THE TREATMENT OF MALARIA IRM LLC (BM) 2011-06-16 US disclosed
US-20110144107-A1 COMPOUNDS AND COMPOSITIONS USEFUL FOR THE TREATMENT OF MALARIA IRM LLC (BM) 2011-06-16 US disclosed
EP-2297097-A2 COMPOUNDS AND COMPOSITIONS USEFUL FOR THE TREATMENT OF MALARIA IRM LLC (BM) 2011-03-23 EP disclosed
WO-2009152356-A2 COMPOUNDS AND COMPOSITIONS USEFUL FOR THE TREATMENT OF MALARIA IRM LLC (BM) 2009-12-17 WO disclosed
WO-2009152356-A2 COMPOUNDS AND COMPOSITIONS USEFUL FOR THE TREATMENT OF MALARIA IRM LLC (BM) 2009-12-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110144107-A1 COMPOUNDS AND COMPOSITIONS USEFUL FOR THE TREATMENT OF MALARIA G6PD, DHFR, SGMS1 NPC1 120/4885RAB9A 2585/4885L3MBTL1 3493/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.